# Allopregnanolone as a Regenerative Treatment for Parkinson's Disease

> **NCT06263010** · PHASE1 · COMPLETED · sponsor: **Roberta Brinton** · enrollment: 10 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** Allopregnanolone

## Key facts

- **NCT ID:** NCT06263010
- **Lead sponsor:** Roberta Brinton
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-12
- **Primary completion:** 2025-07-15
- **Final completion:** 2025-07-15
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06263010

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06263010, "Allopregnanolone as a Regenerative Treatment for Parkinson's Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06263010. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*